Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals IncfiledCriticalXenon Pharmaceuticals Inc
Priority claimed from PCT/US2020/063471external-prioritypatent/WO2021113757A1/en
Publication of MA56958A1publicationCriticalpatent/MA56958A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Selon certains modes de réalisation, la présente invention concerne des méthodes et des utilisations pour traiter la douleur chez un sujet, les méthodes comprenant l'administration par voie orale d'une quantité thérapeutiquement efficace de n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-diméthylphényl]-3,3-diméthylbutanamide (composé a), au sujet nécessitant un tel traitement. La présente invention concerne également diverses méthodes améliorées de thérapie et d'administration du composé a.In some embodiments, the present invention relates to methods and uses for treating pain in a subject, the methods comprising orally administering a therapeutically effective amount of n-[4-(6-fluoro-3 ,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (compound a), to the subject in need of such treatment. The present invention also relates to various improved methods of therapy and administration of compound a.
MA56958A2019-12-062020-12-04
Use of a kv7 potassium channel opener for the treatment of pain
MA56958A1
(en)
COSMETIC USE OF A COMPOSITION COMPRISING AT LEAST ONE OXAZOLIN AS AN ACTIVE INGREDIENT, AS SLIMMING AND / OR FOR PREVENTING AND / OR TREATING CELLULITE